SINOMAB

中國抗體製藥有限公司
SinoMab BioScience Limited
(Incorporated in Hong Kong with limited liability)

Stock Code: 3681

2021 Interim Results

Quick Glance at SinoMab

- **First Hongkong-based listed biopharmaceutical company** dedicated to the research, development, manufacturing and commercialization of therapeutics for **the treatment of autoimmunological diseases**
- Focuses on therapeutics for **autoimmune diseases** including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), asthma and pemphigus vulgaris (PV) etc.
- **Headquarters and** R&D base in Hongkong, Production base in mainland China
- Vision: to become a **global leader** in the **innovation of therapeutics for immunological and other debilitating diseases**

01 Business Highlights

Our Pipeline



Flagship Product SM03

- As of 30 June 2021, a total of 408 patients have been enrolled into SM03 Phase III clinical trials for RA and an interim analysis was completed in June 2020, in which safety data were generally in line with those in Phase II trials
- Expect to complete patient enrollment for SM03's Phase III clinical trial for RA by the end of 2021 at the earliest, and plan to file Biologics Licence Application (BLA) with the NMPA in the second half of 2022 at the earliest
- Expect to initiate Phase II clinical study for SLE in the second half of 2021 at the earliest
- **Expect to commercialize SM03 by the second half of 2023**

Key Product SN1011

- Currently in Phase I clinical trial in Australia, evaluating safety and tolerability of SN1011 in a group of healthy adult subjects, including both single ascending dose ("SAD") and multiple ascending dose ("MAD") studies. As at 29 April 2021, a total number of 56 Caucasian subjects were completed in the Phase I Clinical trial, in which 40 subjects enrolled in SAD part and 16 subjects enrolled in MAD part
- On 15 January 2021, first healthy subject was successfully dosed in Phase I clinical trial in Shanghai; on 23 July 2021, SN1011 has completed last subject last visit in a Phase I dose-escalation study in China, in which 71 healthy subjects were enrolled that none of the subjects reported serious adverse event (SAE)
- On 23 June 2021, an Investigational New Drug (IND) application for the treatment of PV was also approved by the NMPA which is the first BTK inhibitor known for the treatment of PV in China in clinical stage with huge unmet clinical needs
- Initiating Phase II clinical study for PV in China and **plans to initiate Phase II clinical study for SLE in the near future**
- On 16 September 2021 (subsequent to the Reporting Period), we entered into a License Agreement with Suzhou Sinovent (together with the Company, as the licensor) and Everest HK (as the licensee) to out-license the right to develop and commercialize SN1011 globally for the treatment of renal diseases

Key Product SM17

- Generating and collecting necessary data for IND filing; production process development is completed, and clinical batch for Phase I trials is now under manufacturing. Preliminary toxicological studies demonstrated that SM17 is well tolerated at pharmacologically active dose levels in cynomolgus monkeys.
- Compiling the dossier for IND filing globally by the second half of 2021, and now conducting in-house proof-of-concept (POC) studies
- **Intend to enter into human clinical trials by the first quarter of 2022**

Other Drug Candidates

SM06

- Currently optimising production and speeding up the filing for clinical studies in the US, expect to obtain IND approval in the second half of 2022 at the earliest
- To engage regulatory authorities to initiate clinical trials of SM06 once SM03 is commercialised

SM09

- Continue to optimise production and expect to complete pre-clinical research in 2 years

TNF2

- Production cell lines, cell banks and manufacturing process have been established
- Optimising production and expect to complete pre-clinical research in 2 years

Our Production Base

The administrative facilities have been in operation since late 2020

R&D laboratory is under commissioning and is expected to be fully equipped and be in full operation in the second half of 2021.

Suzhou Production Base

PRC Headquarters

Located in Suzhou Dushu Lake High Education Town, with a total floor area of approximately **75,000 sq.m**

Plan to build an R&D centre and a production base, with a production capacity **over 32,000L**

Foundation works have been completed; Superstructure works have been commenced and are expected to be completed by late 2022

Haikou Production Base

Currently in use for producing clinical drugs

Expanded its total operational area from approximately 4,526 sq.m **to approximately 19,163 sq.m with 1,200L capacity**, which is sufficient for clinical and initial marketing needs

Consists of **a clean area, a controlled-not-classified (CNC) area, quality control laboratories, etc.**

02 Financial Performance

Total comprehensive loss



RMB '000

Net cash flows used in operating activities



RMB '000

Net cash flows used in financing activities



RMB '000

Capital expenditure



RMB '000

R&D Costs



RMB '000

Breakdown of R&D Costs



RMB '000

03 Future Strategies

Strategic Layout

- Established a full-spectrum platform integrating in-house capabilities across the industry chain
- Entered into a long-term collaboration with D2M Biotherapeutics Limited for the identification of novel drug targets
- **Well prepared for commercialisation**, backed by production facilities and sales team to be assembled

Commercialisation

- Expect to **build up a sales team by 2022**, covering a majority of provinces and municipalities in China
- Actively exploring and identifying opportunities for collaboration or partnership, including but not limited to licencing in or licencing out

2021 | 2022 | ...

Albeit uncertainties associated with COVID-19, we expect to build up our sales team by 2022.

Future Strategies

We are committed to establishing ourselves as a global leader in the innovation of therapeutics for immunological diseases.



"Since establishment, SinoMab has always been committing to antibody R&D. With 20 years of experience, we still do not forget our original intention, we are committed to discovering and developing novel drug targets and thus advancing treatments for immunological diseases. We hope to fight for patients' well-being while fulfilling our promise to shareholders and society."

Dr. Shui On LEUNG
Chairman, Executive Director and Chief Executive Officer